Variables determinantes del drag-flick en jugadoras de hockey hierba

El penalti córner es una de las situaciones de juego más importantes en el hockey hierba. Las mujeres utilizan menos el drag-flick que los hombres. Los objetivos de este estudio fueron describir los parámetros cinemáticos del drag-flick en jugadoras especialistas y hallar las variables determinantes en el rendimiento en este gesto técnico en jugadoras de hockey. Se analizaron quince lanzamientos de cinco lanzadoras con 6 cámaras del sistema de captura automática VICON registrando a 250 Hz. Para la comparación de medias se utilizó un análisis no paramétrico Kruskall Wallis de un factor (sujeto). Aquellos parámetros en los que se hallaron diferencias significativas, se compararon por pares por medio de una U de Mann Whitney. Las jugadoras 1 (22,5 ? 0,9 m/s) y 3 (22,6 ? 0,7 m/s) registraron velocidades de salida de la bola superiores (p < 0,001) a todas las demás jugadoras (19,1 ? 0,7 m/s jugadora 2; 20,5 ? 0,4 m/s jugadora 4 y 19,9 ? 0,4 m/s jugadora 5). La jugadora 1 basa su aceleración final en un doble apoyo largo, con una secuencia de velocidades y una distancia recorrida lo más amplia posible. Sin embargo, jugadora 3 basa su velocidad en la carrera previa, y en una secuencia de movimientos explosiva. Las características individuales de cada jugadora juegan un papel importante en la elección de una estrategia técnica u otra de lanzamiento

Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis on the importance, screening and vaccination in inflammatory bowel disease patients

Malaltia de Crohn; Colitis ulcerosa; VacunacióEnfermedad de Crohn; Colitis ulcerosa; VacunaciónCrohn's disease; Ulcerative colitis; VaccinationPatients with inflammatory bowel disease (IBD) may require different immunosuppressive treatments throughout their illness. It is essential to assess the immunization status of patients at diagnosis or, if this is not possible, at least before the beginning of immunosuppressive therapy and, subsequently, administering the appropriate vaccines. Therefore, the aim of this work is to establish clear and concise recommendations on vaccination in patients with IBD in the different settings of our clinical practice including vaccination in children, during pregnancy, breastfeeding or on trips. This consensus document emphasises the differences between inactivated and attenuated vaccines and the different degrees of immunosuppression and correlates them with the administration of both mandatory and optional vaccines recommended to our patients with IBD. Finally, as a summary, 17 recommendations are established based on the available scientific evidence and expert opinion. A multidisciplinary team with extensive experience in IBD and vaccination, made up of specialists in gastroenterology, paediatrics, nursing and pharmacy, has participated in the preparation of these recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.Los pacientes con enfermedad inflamatoria intestinal (EII) pueden requerir diferentes tratamientos inmunosupresores a lo largo del curso de su enfermedad. Por ello, es fundamental evaluar el estado de inmunización en el momento del diagnóstico o, si no es posible, siempre antes de iniciar un tratamiento inmunosupresor, y administrar las vacunas apropiadas. El objetivo del presente documento es establecer unas recomendaciones claras y concisas sobre la vacunación en pacientes con EII en diferentes escenarios de práctica clínica, incluyendo situaciones especiales como la vacunación en la edad pediátrica, el embarazo, la lactancia o en viajes al extranjero. Se presentan las diferencias entre vacunas inactivadas y atenuadas, los diferentes grados de inmunosupresión y su relación con las pautas de administración de las diferentes vacunas (tanto obligatorias como opcionales) recomendadas a los pacientes con EII. En el documento, se establecen 17 recomendaciones basadas en la evidencia científica disponible y opinión de expertos. En la elaboración de estas recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa ha participado un equipo multidisciplinar con amplia experiencia en EII y vacunación formado por especialistas de gastroenterología, pediatría, enfermería y farmacia

STAG3 is a strong candidate gene for male infertility

Oligo- and azoospermia are severe forms of male infertility. However, known genetic factors account only for a small fraction of the cases. Recently, whole-exome sequencing in a large consanguineous family with inherited premature ovarian failure (POF) identified a homozygous frameshift mutation in the STAG3 gene leading to a premature stop codon. STAG3encodes a meiosis-specific subunit of the cohesin complex, alarge proteinaceous ring with DNA-entrapping ability that ensures sister chromatid cohesion and enables correct synapsis and segregation of homologous chromosomes during meiosis. The pathogenicity of the STAG3 mutations was functionally validated with a loss- of-function mouse model for STAG3 in oogenesis.However,and sincenone of the male members of this family was homozygous for the mutant allele, we only could hypothesized its putative involvement inmale infertility. In this report,we show that male mice devoid of Stag3 display a severe meiotic phenotype that includes a meiotic arrest at zygonema-like shortening of their chromosome axial elements/lateral elements, partial loss of centromeric cohesion at early prophase and maintenance of the ability to initiate but not complete RAD51- and DMC1-mediated double-strand break repair,demonstrating that STAG3 is a crucial cohesin subunit in mammalian gametogenesis and supporting our proposal that STAG3 is a strong candidate gene for human male infertility. © The Author 2014. Published by Oxford University Press. All rights reserved.This work was supported by grant SAF2011-25252 and Junta de Castilla y León (EL and AMP). SC and RAV are supported by the University Paris Diderot-Paris7, the Ligue Nationale contre le Cancer, the Centre National de la Recherche Scientifique (CNRS) and the GIS-Institut des Maladies Rares.Peer Reviewe

Aumento del riesgo de enfermedad cardiovascular en pacientes con enfermedad celíaca

En pacientes con enfermedad celíaca (EC), se ha observado mayor incidencia de eventos cardiovasculares que en controles, sin la presencia de factores de riesgo aterogénico clásicos. El objetivo de este estudio fue evaluar los factores de riesgo nóveles y biomarcadores de inflamación y enfermedad cardiovascular en pacientes con EC, con presentación típica y atípica. Fueron seleccionados 14 pacientes con EC sin tratamiento y controles pareados por sexo y edad. Se determinaron parámetros hematológicos, indicadores del metabolismo de los hidratos de carbono, proteína C reactiva ultrasensible (PCRus), per- fil lipoproteico y actividades de proteína transportadora de colesterol esterificado (CETP) y fosfolipasa A2 asociada a lipoproteínas (Lp-PLA2). Los pacientes con EC presentaron niveles plasmáticos mayores de insulina (7,2 mU/l vs. 4,4 mU/l; p<0,05) y mayor índice HOMA-IR (1,45 vs. 0,98; p<0,05) que los controles. Por otro lado, se observó menor concentración de colesterol-HDL (50 vs. 62 mg/dl; p<0,05), mayor cociente triglicéridos/colesterol-HDL y niveles de PCRus más altos (4,56 vs. 1,17 mg/l; p<0,05) en los pacientes que en los controles. Al comparar a los pacientes con presentación típica (n=8) y atí- pica (n=6), aquellos con presentación típica mostraron menores niveles de apo A-I (128 vs. 178 mg/dl; p<0,01) y aumento del cociente apo B/apo A-I (0,72 vs. 0,43; p<0,05), así como mayor actividad de LpPLA2 (7,9 umol/ml.h vs. 6,15 umol/ml.h; p<0,05). La interacción de las alteraciones descriptas durante períodos de tiempo prolongados en una condición patológica crónica como la EC constituirían un mayor riesgo de desarrollo de enfermedad cardiovascular aterosclerótica.In patients with celiac disease (CD), it has been reported higher incidence of cardiovascular events than in controls, without the presence of classical atherogenic risk factors. The aim of this study was to evaluate the novel risk factors and biomarkers of inflammation and cardiovascular disease in patients with CD, with typical and atypical presentation. We selected 14 patients with CD without treatment and 14 healthy sex and age-matched controls. Haematological parameters, indicators of carbohydrates metabolism, high sensitive C reactive protein (hsCRP), lipoprotein profile and the activities of cholesteryl ester transfer protein (CETP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) were determined. CD patients presented higher insulin plasma levels (7.2 mU/l vs. 4.4 mU/l, p <0.05) and increased HOMA-IR index (1.45 vs. 0.98, p <0.05) than controls. On the other hand, lower HDLcholesterol concentration (50 vs. 62 mg/dl, p<0.05), higher TG/HDL-cholesterol ratio and increased hsCRP levels (4.56 vs. 1.17 mg / l, P <0.05) were observed in comparison with control subjects. When comparing patients with typical (n=8) and atypical (n=6) presentation, the former showed lower apo A-I levels (128 vs. 178 mg/dl, p<0.01), and higher apo B/apo A-I ratio (0.72 vs. 0.43, p<0.05) and LpPLA2 activity (7.9 umol/ml.h vs. 6.15 umol/ml.h, p<0.05). The interaction among the alterations above described during long periods of time in a chronic pathological condition such as CD could constitute higher risk of development of atherosclerotic cardiovascular disease.Fil: Menafra, Martín. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Meroño, Tomás. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Matoso, María Dolores. Hospital Italiano; ArgentinaFil: Boero, Laura Estela. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gomez Rosso, Leonardo Adrián. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Saez, María Soledad. Hospital Italiano; ArgentinaFil: Sorroche, Patricia Beatriz. Hospital Italiano; ArgentinaFil: de Paula, P.. Hospital Italiano; ArgentinaFil: Brites, Fernando Daniel. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin

Fetal sex modulates developmental response to maternal malnutrition

The incidence of obesity and metabolic diseases is dramatically high in rapidly developing countries. Causes have been related to intrinsic ethnic features with development of a thrifty genotype for adapting to food scarcity, prenatal programming by undernutrition, and postnatal exposure to obesogenic lifestyle. Observational studies in humans and experimental studies in animal models evidence that the adaptive responses of the offspring may be modulated by their sex. In the contemporary context of world globalization, the new question arising is the existence and extent of sex-related differences in developmental and metabolic traits in case of mixed-race. Hence, in the current study, using a swine model, we compared male and female fetuses that were crossbred from mothers with thrifty genotype and fathers without thrifty genotype. Female conceptuses evidence stronger protective strategies for their adequate growth and postnatal survival. In brief, both male and female fetuses developed a brain-sparing effect but female fetuses were still able to maintain the development of other viscerae than the brain (mainly liver, intestine and kidneys) at the expense of carcass development. Furthermore, these morphometric differences were reinforced by differences in nutrient availability (glucose and cholesterol) favoring female fetuses with severe developmental predicament. These findings set the basis for further studies aiming to increase the knowledge on the interaction between genetic and environmental factors in the determination of adult phenotype

CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets

[EN] With the advent of OMICs technologies, both individual research groups and consortia have spear-headed the characterization of human samples of multiple pathophysiologic origins, resulting in thousands of archived genomes and transcriptomes. Although a variety of web tools are now available to extract information from OMICs data, their utility has been limited by the capacity of nonbioinformatician researchers to exploit the information. To address this problem, we have developed CANCERTOOL, a web-based interface that aims to overcome the major limitations of public transcriptomics dataset analysis for highly prevalent types of cancer (breast, prostate, lung, and colorectal). CANCERTOOL provides rapid and comprehensive visualization of gene expression data for the gene(s) of interest in well-annotated cancer datasets. This visualization is accompanied by generation of reports customized to the interest of the researcher (e.g., editable figures, detailed statistical analyses, and access to raw data for reanalysis). It also carries out gene-to-gene correlations in multiple datasets at the same time or using preset patient groups. Finally, this new tool solves the time-consuming task of performing functional enrichment analysis with gene sets of interest using up to 11 different databases at the same time. Collectively, CANCERTOOL represents a simple and freely accessible interface to interrogate well-annotated datasets and obtain publishable representations that can contribute to refinement and guidance of cancer-related investigations at all levels of hypotheses and design. Significance: In order to facilitate access of research groups without bioinformatics support to public transcriptomics data, we have developed a free online tool with an easy-to-use interface that allows researchers to obtain quality information in a readily publishable forma

West Nile virus emergence in humans in Extremadura, Spain 2020

In Spain, the largest human West Nile virus (WNV) outbreak among humans was reported in 2020, constituting the second most important outbreak in Europe that season. Extremadura (southwestern Spain) was one of the affected areas, reporting six human cases. The first autochthonous human case in Spain was reported in Extremadura in 2004, and no other human cases were reported until 2020. In this work, we describe the first WNV human outbreak registered in Extremadura, focusing on the most important clinical aspects, diagnostic results, and control actions which followed. In 2020, from September to October, human WNV infections were diagnosed using a combination of molecular and serological methods (an in-house specific qRT-PCR and a commercial ELISA for anti-WNV IgM and IgG antibodies) and by analysing serum, urine, and/or cerebrospinal fluid samples. Serological positive serum samples were further tested using commercial kits against related flaviviruses Usutu and Tick-borne encephalitis in order to analyse serological reactivity and to confirm the results by neutralisation assays. In total, six cases of WNV infection (five with neuroinvasive disease and one with fever) were identified. Clinical presentation and laboratory findings are described. No viral RNA was detected in any of the analysed samples, but serological cross-reactivity was detected against the other tested flaviviruses. Molecular and serological methods for WNV detection in various samples as well as differential diagnosis are recommended. The largest number of human cases of WNV infection ever registered in Extremadura, Spain, occurred in 2020 in areas where circulation of WNV and other flaviviruses has been previously reported in humans and animals. Therefore, it is necessary to enhance surveillance not only for the early detection and implementation of response measures for WNV but also for other emerging flaviviruses that could be endemic in this area.This research was partially funded by the project PI19CIII/00014 from the Instituto de Salud Carlos III.S

Low-dose statin treatment increases prostate cancer aggressiveness

Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer

Low-dose statin treatment increases prostate cancer aggressiveness

Altres ajuts: NM-M was supported by the Spanish Association Against Cancer (AECC), AECC JP Vizcaya. VT is supported by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the department of health of the Basque Government (2016111109) and the 2016 grant of the AECC (Junta provincial de Bizkaia). LA, AA-A and LV-J were supported by the Basque Government of education. The work of A.C. is supported by the Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (Etortek) and the department of education (IKERTALDE IT1106-16), FERO VIII Fellowship, the BBVA foundation, Severo Ochoa. Excellence Accreditation SEV-2016-0644) and the European Research Council (Starting Grant 336343; Proof of Concept 754627). The participation of AC, VT, NM-M, SF and AZ as part of CIBERONC was co-funded with FEDER funds.Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer

HPC Serverless para tratamiento de datos provenientes del IoT

Se ha demostrado que la ejecución de aplicaciones de HPC en el cloud es una opción viable a las arquitecturas paralelas o distribuidas convencionales, las cuales requieren un alto grado de administración, así como un pobre escalado de recursos. El enfoque tradicional para un usuario usualmente es utilizar al proveedor de Cloud para aprovisionar máquinas virtuales (VM) empleándolas de manera similar a una infraestructura local, con el consiguiente problema de la administración de recursos sumado a la degradación de la performance de las aplicaciones por la contextualización de los ambientes virtualizados. Serverless computing, permite a un usuario ejecutar código escrito en el lenguaje de programación de su elección, sin tener que aprovisionar primero una máquina virtual. Por otro lado, la elasticidad, disponibilidad, escalabilidad y la tolerancia a fallas son proporcionadas de manera transparente por el proveedor cloud. De esta manera es posible disminuir la complejidad de la administración de la infraestructura para el desarrollador, permitiéndole que se centre en la lógica de la aplicación. Y además surgen ventajas económicas, al pagar solo por el tiempo de uso. La presente línea de investigación se centra en el desafío de evaluar el costo, no solo monetario sino también de performance, de migrar aplicaciones de HPC a entornos serverless. Esta evaluación permitirá que se pueda tomar la decisión que infraestructura se usará con la finalidad que se obtenga el mejor beneficio de performance.Red de Universidades con Carreras en Informátic